Amarantus BioScience Holdings “AAIC 2014: Understanding the Data Being Presented – LymPro Test(r) Version 2”

Publishing & Media

Share Tweet

Amarantus BioScience Holdings “AAIC 2014: Understanding the Data Being Presented – LymPro Test(r) Version 2”

New York, NY / ACCESSWIRE / July 9, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman’s Blog, written by the Company’s CEO, Mr. Gerald Commissiong. is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his blog Mr. Commissiong expands upon what specific data will be presented by the Company at the Alzheimer’s Association International Conference (AAIC) on July 14th and 15th as well as the #C4CT Summit on July 31st. Mr. Commissiong states, “We are excited to be presenting the Company’s first data sets on LymPro to the scientific community.” Read the full blog post from Mr. Gerald Commissiong on (

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment.